Nanoco shares shrink as disposal of business ruled out

Nanoco shares plunged 21% to 6.8p after the company abandoned a sale of its operating assets and IP, citing lack of firm offers and deal complexity (including national security considerations). Management will instead pursue value via investment in existing business lines, cut gross monthly cash operating costs to £300k-400k, advance joint development agreements with two Asian chemical partners, and continue IP litigation (against Shoei Chemical) after concluding its case with LG Electronics; CEO Dmitry Shashkov will leave in February with CFO Liam Gray as interim CEO and two non-executive directors to step down in April 2026.

Analysis

Market structure: Nanoco (LSE:NANO) shrinking the sale process and cutting to £300–400k/month cash burn (≈£3.6–4.8m/year) crystallises downside for minority equity holders and benefits counterparties with liquid IP exposure or cash-rich acquirers who avoided a complex carve‑up. Competitors and incumbent display/materials suppliers gain pricing/contract leverage if Nanoco cannot scale – expect weak bargaining power for Nanoco in joint dev agreements and limited market-share gain from existing customers over 6–24 months. Cross-asset: NANO equity volatility will stay elevated (near-term >20–30% realized), negligible direct corporate bond impact but raises idiosyncratic risk premia in small‑cap UK tech; GBP moves immaterial except vs. EUR/JPY for Asian partner invoices.

Risk assessment: Tail risks include adverse national‑security export rulings or an adverse Shoei litigation loss that could trigger accelerated insolvency (low prob, high impact within 6–18 months). Immediate (days) risk—further selling and management vacuum; short-term (weeks/months)—cash runway and partner JDA execution; long-term (quarters/years)—IP monetisation through litigation/licensing or dilution. Hidden dependencies: success hinges on confidentiality-sensitive Asian JV execution and remaining cash reserves (check cash balance within 30 days); shareholder dilution is a high-probability second‑order effect.

Trade implications: Direct tactical: short/sell NANO (LSE:NANO) size 2–4% portfolio, target 4p, stop 10p, horizon 3–9 months, or buy 3–6 month puts if listed; pair trade long established specialty-chemicals (e.g., Solvay SOLB.BR, Cabot Corp CBT) vs short NANO to capture relative stability. Options: if volatility >30% consider buying puts (3–6m) or put spreads to limit capital; avoid writing naked calls. Sector rotation: reduce small-cap UK tech/nanomaterials exposure by 50% and redeploy into large-cap materials/chemicals for 6–12 months.

Contrarian angles: Consensus presumes inevitable decline; downside may be overstated if litigation wins yield >£10m recoveries or Asian JDA converts to licensing revenue—binary upside in 6–24 months. Historical parallel: small IP-rich firms (e.g., Acacia Research-style outcomes) show litigation/licensing can re-rate equity after multi-year stretches; position sizing should therefore be asymmetric (small short, small optional long via cheap long‑dated calls or equity on sub-1% basis). Watch for management clarity and cash updates as catalyst to reverse sentiment.

Key Decisions for Investors

• Establish a cautious short position in Nanoco (LSE:NANO) sized 2–4% of portfolio via stock/CFD (if options unavailable), target exit at 4p and hard stop at 10p, horizon 3–9 months to capture execution risk and cash‑runway re-pricing.
• Initiate a relative-value pair: long 2–3% in large-cap specialty-chemicals (examples: Solvay SOLB.BR or Cabot Corp CBT) and short 2% NANO to hedge sector/commodity exposure; hold 6–12 months.
• If listed options exist, buy 3–6 month NANO puts or a put spread (pay max premium) to express downside while limiting capital; if options unavailable, use short stock with defined stop-loss.
• Cap total exposure to NANO-related trades at 5% portfolio and require two catalysts before increasing exposure: 1) company cash balance disclosure within 30 days showing >£4m runway, 2) outcome update on Shoei litigation within 6–18 months.